Niva Bupa Health Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Insurance | Market Cap: ₹15.3K Cr
October saw over 50% growth in retail sales, driven by GST reduction from 18% to 0%, enhancing affordability and demand. Growth with profit remains the company’s core mantra as they continue to invest in health insurance opportunities.
From Niva Bupa Health's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹83.2
Market Cap
₹15.3K Cr
P/E Ratio
87.7
How does Niva Bupa Health rank in Insurance?
Compare Niva Bupa Health against every Insurance company this quarter on revenue, margins and earnings-call signals.
Niva Bupa Health — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹345 Cr.
Full financials →📊 Revenue & Sales Performance
- →October saw over 50% growth in retail sales, driven by GST reduction from 18% to 0%, enhancing affordability and demand.
- →Increased renewal rates, with October renewal rates higher by 100 basis points versus last year.
- →Retail health grew 28% in H1, with approximately 20% of growth from volume (more lives covered) and 7% from ticket size improvement.
- →Strong growth in SME segment within group health, close to 50% growth, contributing around 70-75% of group policies by volume.
- →Multi-channel approach driving SME growth including digital, agency, brokers, and banks.
- →Anticipate continued growth from improved conversion rates, digital channels performing 1.5x average organization growth.
- →No immediate price hike planned; monitoring market conditions post-GST impact.
- →Long-term ROE guidance remains mid-to-high teens by FY '29, indicating confidence in sustained growth.
📈 Profitability & Margins
- →Growth with profit remains the company’s core mantra as they continue to invest in health insurance opportunities.
- →GWP grew 23% in H1 FY '26 on a like-to-like basis.
- →Profit after tax more than doubled from INR 60 crores (last year H1) to INR 132 crores (current H1).
- →Combined ratio improved by 105 bps to 103.1%, driven by expense ratio reduction despite a slight loss ratio increase.
- →Retail loss ratio stabilized at last year’s levels (68.1%).
- →Expense of management ratio improved by 3.7%, aiding profitability.
- →October demand showed significant growth (50%+ in retail for October alone) due to GST reduction and enhanced product offerings.
- →Investments in AI, distribution expansion (+1000 headcount), and technology (microservices platform) aim to drive scalable, profitable growth.
- →Management will monitor pricing and portfolio economics, with no price hikes planned in the near term, suggesting stable earnings trajectory.
🏗️ Capital Expenditure Plans
- →Niva Bupa is making significant investments to pursue health insurance growth with profit as their mantra.
- →Increased distribution headcount by more than 1,000 field staff this year.
- →Set up an AI lab to explore capabilities offered by Generative AI, including customer projects recognized globally.
- →Launched ReAssure 3.0, a modern microservices-based core system aimed at transforming product launch and customer service.
- →Investments focus on sales, customer experience enhancement, and cost optimization.
- →Industry-wide commitments include sizable annual spends on awareness campaigns over the next 3 years.
- →Initiatives include common empanelment of 3,500-4,000 hospitals and efforts toward standardization of protocols and hospitalization indications as levers to control claims cost.
💰 Fundraising & Capital Structure
- →There is no mention of any current or future new fundraising through debt or equity in the provided transcript.
- →The capital contribution was highlighted with INR 800 crores raised previously, including some private market raising, but no new fundraising plans were indicated.
- →Investment strategy focuses primarily on bonds with a minor allocation (~6%) in Nifty ETF, AIF, InvIT, and REIT, without plans to ramp up equity.
- →No explicit comment or plan for additional equity or debt raising in the near term was discussed.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Niva Bupa Health Q2 FY26 results?
October saw over 50% growth in retail sales, driven by GST reduction from 18% to 0%, enhancing affordability and demand. Growth with profit remains the company’s core mantra as they continue to invest in health insurance opportunities.
What is Niva Bupa Health share price analysis?
Niva Bupa Health currently shows a neutral. The stock trades at a P/E of 87.7 with a market cap of ₹15,278 Cr. Investors should review the full earnings analysis for detailed insights.
Is Niva Bupa Health planning capital expenditure?
Niva Bupa is making significant investments to pursue health insurance growth with profit as their mantra.
Keep Niva Bupa Health on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.